NCT02675322View on ClinicalTrials.gov

Danlou Tablets to Prevent Left Ventricular Remodeling

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

December 31, 2015

Conditions
Left Ventricular RemodelingAcute Myocardial Infarction
Interventions
DRUG

Danlou Tablets

Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).

OTHER

Placebo

Placebo with no chemical effects.

All Listed Sponsors
lead

shuai Mao

OTHER

NCT02675322 - Danlou Tablets to Prevent Left Ventricular Remodeling | Biotech Hunter | Biotech Hunter